P/OSPeptideOS evidence & status map
OPEN SOURCE MEDICINE FOUNDATIONLast reviewed 2026-10-10No dosing · no vendors · no advicesource file

← All compounds · evidence tier first, by design

Evidence tier for each claimed use · ← established · unknown →
UseE1E2E3E4E5E6E7E8
E1 Weight reduction in obesity or overweight (the main use it is sold for)E1
E2 Type 2 diabetes: glycaemic controlE2
E2 Knee osteoarthritis pain with obesityE2
E2 Obstructive sleep apnoea with obesityE2
E3 Liver fat (metabolic dysfunction-associated steatotic liver disease)E3
Class B · Investigational

Retatrutide

Synthetic lipidated peptide containing non-coded amino acids; full structure not verified for this record.

Non-standard residues or modifications: no plain one-letter sequence

Codes: LY3437943

An investigational synthetic peptide from Eli Lilly that activates three hormone receptors: GIP, GLP-1 and glucagon. It is in phase 3 development for obesity, type 2 diabetes and related conditions. It is not approved in any jurisdiction checked. The UK MHRA states it is not authorised and that products sold under the name are sold illegally; case reports describe harm after use of online-purchased material.

  • US B investigational
  • EU B investigational
  • UK B investigational
  • CA B investigational
  • AU B investigational
  • JP B investigational
  • CN B investigational

01Regulatory status, by jurisdiction

Standing notice. This compound is an investigational drug. It is not approved in any jurisdiction. There is no lawful supply. Any material sold under this name is of unverified origin, and is neither manufactured nor tested to pharmaceutical standards.
JurisdictionStatusDetail and primary source
USInvestigationalNo Drugs@FDA application found for retatrutide (openFDA Drugs@FDA query by active ingredient returns no records). Phase 3 trials sponsored by Eli Lilly are registered on ClinicalTrials.gov.
“"code": "NOT_FOUND", "message": "No matches found!"”
openFDA Drugs@FDA API query: active ingredient retatrutide · retrieved 2026-10-10
EUInvestigationalRetatrutide does not appear in the EMA medicines dataset (2,748 records of centrally processed medicines, timestamp 2026-10-10).
“"total_records": 2748, "timestamp": "2026-10-10T06:02:36Z"”
EMA medicines data (JSON report) · retrieved 2026-10-10
UKInvestigationalMHRA press release (24 July 2026) states retatrutide is not authorised in the UK.
“It has not been authorised for use in the UK, meaning anyone selling this product is doing so illegally.”
No summer shortcut for safe weight loss (MHRA) · retrieved 2026-10-10
CAInvestigationalHealth Canada Drug Product Database active-ingredient query for retatrutide returns an empty result.
“[]”
Health Canada Drug Product Database API: active ingredient retatrutide · retrieved 2026-10-10
AUInvestigationalTGA Product Information repository search for retatrutide returns no documents.
“Search PI Trade Names and Active Ingredients containing retatrutide . 0 Documents available.”
TGA eBS - Product and Consumer Medicine Information (search: retatrutide) · retrieved 2026-10-10
JPInvestigationalRetatrutide does not appear in the PMDA List of Approved Products (New Drugs), which covers approvals through February 2026; later approvals would not be shown.
“April 2004 to February 2026”
PMDA List of Approved Products: New Drugs (April 2004 to February 2026) · retrieved 2026-10-10
CNNot yet verified from a primary source. No status is shown rather than an unsourced one.

Sport (WADA): Prohibited · class S0. “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development” WADA source

02What the human evidence shows

E1

Weight reduction in obesity or overweight (the main use it is sold for)

n/cpublished human RCTs
n/cpublished human trials
17registered studies
1with posted results

n/c: not counted here; see the cited review.

Two published phase 3 trials and one phase 2 trial. TRIUMPH-1 (2,339 adults without diabetes, 80 weeks): mean weight change -17.6% to -25.0% across dose groups versus -3.9% with placebo. TRIUMPH-2 (1,152 adults with obesity and type 2 diabetes, 80 weeks): -11.9% to -18.8% versus -5.1%. The phase 2 trial (338 adults, 48 weeks) reported -8.7% to -24.2% versus -2.1%. Phase 3 results of TRIUMPH-3 and TRIUMPH-4 (both completed on ClinicalTrials.gov) were not located in a publication.

  • [1] TRIUMPH-1: weight change -17.6% to -25.0% vs -3.9% with placebo at 80 weeks in adults with obesity without diabetes
  • [2] TRIUMPH-2: weight change -11.9% to -18.8% vs -5.1% with placebo at 80 weeks in obesity with type 2 diabetes
  • [3] Phase 2: weight change up to -24.2% vs -2.1% with placebo at 48 weeks

Registered-study counts: ClinicalTrials.gov intervention search “retatrutide AND obesity”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

E2

Type 2 diabetes: glycaemic control

n/cpublished human RCTs
n/cpublished human trials
14registered studies
1with posted results

n/c: not counted here; see the cited review.

One published phase 3 trial (TRANSCEND-T2D-1, 537 adults managed with diet and exercise alone, 40 weeks): HbA1c fell 1.69 to 1.94 percentage points versus 0.81 with placebo. A phase 2 trial (281 participants) also reported HbA1c reductions. Phase 3 trials versus semaglutide (TRANSCEND-T2D-2) and in renal impairment (TRANSCEND-T2D-3) have not reported.

  • [4] HbA1c change -1.69% to -1.94% vs -0.81% with placebo at 40 weeks
  • [5] Phase 2: dose-dependent HbA1c reductions at 24 weeks in type 2 diabetes

Registered-study counts: ClinicalTrials.gov intervention search “retatrutide AND type 2 diabetes”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

E2

Knee osteoarthritis pain with obesity

n/cpublished human RCTs
n/cpublished human trials
1registered studies
0with posted results

n/c: not counted here; see the cited review.

In a 574-participant knee osteoarthritis subgroup of TRIUMPH-1, WOMAC pain scores improved more with retatrutide than placebo (differences -1.6 and -1.8 points on a 10-point scale, hybrid estimand). The dedicated knee osteoarthritis trial (TRIUMPH-4, NCT05931367) is completed on ClinicalTrials.gov but no publication was located.

  • [1] WOMAC pain differences -1.6 and -1.8 points vs placebo in the knee osteoarthritis subgroup

Registered-study counts: ClinicalTrials.gov intervention search “retatrutide AND osteoarthritis”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

E2

Obstructive sleep apnoea with obesity

n/cpublished human RCTs
n/cpublished human trials
0registered studies
0with posted results

n/c: not counted here; see the cited review.

In a 243-participant obstructive sleep apnoea subgroup of TRIUMPH-1, the apnoea-hypopnoea index fell by about 22 to 24 more events per hour than with placebo (both comparisons P<0.001). No standalone sleep apnoea trial result has been published.

  • [1] AHI differences -24.4 and -21.9 events per hour vs placebo in the sleep apnoea subgroup

Registered-study counts: ClinicalTrials.gov intervention search “retatrutide AND sleep apnea”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

E3

Liver fat (metabolic dysfunction-associated steatotic liver disease)

n/cpublished human RCTs
n/cpublished human trials
2registered studies
0with posted results

n/c: not counted here; see the cited review.

Evidence is a substudy of the phase 2 obesity trial (98 participants with at least 10% liver fat). Relative liver-fat change at 24 weeks ranged from -42.9% to -82.4% across dose groups versus +0.3% with placebo. Liver fat is a surrogate endpoint; no histology or liver-outcome trial has reported.

  • [6] Relative liver-fat change -42.9% to -82.4% vs +0.3% with placebo at 24 weeks (n=98)

Registered-study counts: ClinicalTrials.gov intervention search “retatrutide AND liver”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

Key registered trials

NCTTitle (as registered)PhaseStatus
NCT05929066A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight3Completed
NCT05929079A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight3Completed
NCT05882045A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease3Completed
NCT05931367A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee3Completed
NCT06662383A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity3Active, not recruiting
NCT06859268A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity3Active, not recruiting
NCT06383390The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)3Active, not recruiting
NCT06354660Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)3Completed
NCT06260722Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)3Active, not recruiting
NCT06297603Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)3Active, not recruiting
NCT04881760A Study of LY3437943 in Participants Who Have Obesity or Are Overweight2Completed
NCT04867785A Study of LY3437943 in Participants With Type 2 Diabetes2Completed

03Safety signals

S2Substantial controlled-trial safety data

There are no adequate human safety data. The absence of reported harm is not evidence of safety.

  • Gastrointestinal adverse events [2]
    In TRIUMPH-2, diarrhoea occurred in 27-34% and nausea in 14-28% of retatrutide groups versus 13% and 8% with placebo. Treatment discontinuation for adverse events or death reached 12% in one dose group versus 5% with placebo.
  • Dysaesthesia (abnormal skin sensation) and hypotension [2]
    In TRIUMPH-2, dysaesthesia occurred in 4-7% versus 1% and hypotension in 1-6% versus <1% with placebo, increasing with dose.
  • Heart rate increase [3]
    In the phase 2 obesity trial, dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.
  • Harm after use of unlicensed online product [7]
    Case report: a man with type 1 diabetes developed vomiting, diarrhoea, ketonaemia and acute kidney injury after self-administering an online-purchased product marketed as retatrutide (concurrent Shigella infection). Product identity was not confirmed.

04What is unknown

  • Effect on cardiovascular and kidney outcomes; TRIUMPH-Outcomes (NCT06383390) is ongoing
  • Safety beyond 80 weeks of exposure, the longest duration in published randomised trials
  • Mechanism, course and reversibility of the dysaesthesia signal seen in phase 3
  • Results of completed phase 3 trials TRIUMPH-3 and TRIUMPH-4, which were not located in a peer-reviewed publication as of 2026-10-10
  • Identity, purity, sterility and content of material sold online under the retatrutide name; no lawful supply exists and no systematic assay data were located

05Product quality

No independent purity results have been published for this compound yet. The purity programme will publish full methods and vendor-named results, passes and failures, once its protocol has had legal review.

06Citations

  1. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (2026). doi:10.1056/nejmoa2604169
  2. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial (2026). doi:10.1016/s0140-6736(26)01861-1
  3. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (2023). doi:10.1056/NEJMoa2301972
  4. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (2026). doi:10.1016/s0140-6736(26)00967-0
  5. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (2023). doi:10.1016/S0140-6736(23)01053-X
  6. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (2024). doi:10.1038/s41591-024-03018-2
  7. Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. doi:10.7759/cureus.115260

Every DOI is resolved against Crossref and every NCT number against ClinicalTrials.gov, title for title, before publication. Regulatory sources are cited inline above with a verbatim quote and retrieval date.

07Mechanism

Retatrutide is a single peptide with agonist activity at the GIP, GLP-1 and glucagon receptors.

Mechanism is placed last on purpose: a plausible mechanism is not evidence that a compound works in people.

Reviewed by OSMF research team (AI-assisted, source-verified) on 2026-10-10. Found an error? It goes in the corrections log: report it.